Grifols (GRFS) vs. Its Rivals Head to Head Survey

Grifols (NASDAQ:GRFS) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Grifols to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, valuation, dividends, earnings and risk.

Volatility & Risk

Grifols has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Grifols’ competitors have a beta of 1.14, meaning that their average stock price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Grifols and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1	2	0	0	1.67
Grifols Competitors	9789	15058	45310	1572	2.54

Grifols presently has a consensus target price of $9.00, suggesting a potential upside of 5.14%. As a group, “Biotechnology” companies have a potential upside of 97.81%. Given Grifols’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Grifols has less favorable growth aspects than its competitors.

Profitability

This table compares Grifols and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Grifols Competitors	-9,046.59%	-199.78%	-30.61%

Earnings & Valuation

This table compares Grifols and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grifols	$8.51 billion	$454.82 million	45.05
Grifols Competitors	$691.14 million	$10.43 million	-10.01

Grifols has higher revenue and earnings than its competitors. Grifols is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dividends

Grifols pays an annual dividend of $0.09 per share and has a dividend yield of 1.1%. Grifols pays out 47.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.3% and pay out 40.7% of their earnings in the form of a dividend. Grifols lags its competitors as a dividend stock, given its lower dividend yield and higher payout ratio.

Summary

Grifols competitors beat Grifols on 9 of the 15 factors compared.

Grifols Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.